Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/57913| Title: | Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion. | Authors: | Huang H.;Cheah C.;de Holanda Farias J.S.;Elghandour A.;Ong S.Y.;Li Z.;de Farias D.L.C.;Ko B.S.;Hawkes E.;Song Y.;Zincer F.P.;Pavlovsky M.A.;Kim W.S.;Al Mansour M. | Monash Health Department(s): | Monash University - School of Clinical Sciences at Monash Health | Institution: | (Kim) Department of Internal Medicine, Division of Hematology Oncology, Samsung Medical Center, Seoul, South Korea (Kim) Sungkyunkwan University School of Medicine, Seoul, South Korea (Al Mansour) Department of Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs Western Region, Jeddah, Saudi Arabia (Al Mansour) College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia (Cheah) Department of Haematology, Sir Charles Gairdner Hospital, Perth, Australia (Cheah) Medical School, University of Western Australia, Perth, Australia (de Holanda Farias) Hematology Department, Hospital Erasto Gaertner, Curitiba, Brazil (Elghandour) Faculty of Medicine, Alexandria University, Alexandria, Egypt (Hawkes) Olivia Newton John Cancer Research Institute as Austin Health, Heidelberg, Australia (Hawkes) School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia (Huang) National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China (Ko) Department of Internal Medicine, Divisions of Hematology, National Taiwan University Hospital, Taipei, Taiwan (Republic of China) (Ko) Tai Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan (Republic of China) (Ko) Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan (Republic of China) (Ko) School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan (Republic of China) (de Farias) Hospital Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil (Li) Department of Medical Oncology, Sun Yat sen University Cancer Center, Guangzhou, China (Ong) Department of Haematology, Singapore General Hospital, Singapore, Singapore (Pavlovsky) FUNDALEU Clinical Research Center, Buenos Aires, Argentina (Zincer) Department of Hematology, Hospital Angeles Lomas, Mexico, Mexico (Song) Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China |
Issue Date: | 20-Mar-2026 | Copyright year: | 2026 | Publisher: | Taylor and Francis Ltd. | Place of publication: | United Kingdom | Publication information: | Leukemia and Lymphoma. (no pagination), 2026. Date of Publication: 2026. | Journal: | Leukemia and Lymphoma | Abstract: | Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin B-cell lymphoma that presents significant clinical management challenges. Recent advancements in treatment strategies, such as Bruton's tyrosine kinase inhibitors (BTKi), chimeric antigen receptor T-cell (CAR-T) therapy, and chemo-free regimens, have transformed the therapeutic landscape. This expert opinion article, based on insights from 14 experts worldwide, explores the evolving role of autologous stem cell transplantation (ASCT) in MCL management, and the treatment approaches for ASCT-ineligible patients. It discusses the benefits and limitations of emerging therapies, emphasizing personalized treatment approaches to optimize clinical outcomes. Tailoring strategies to individual patient profiles, considering genetic markers, comorbidities, and regional healthcare resources, is crucial. The evolving MCL landscape prioritizes personalized care, with BTKi emerging as an effective first-line option for ineligible ASCT patients and a robust alternative to ASCT. Global collaboration and knowledge sharing are essential to advance MCL treatment and ensure optimal care.Copyright © 2026 Informa UK Limited, trading as Taylor & Francis Group. | DOI: | https://dx.doi.org/10.1080/10428194.2026.2640453 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/57913 | Type: | Article In Press |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.